Who We Are - Merck India | Science and Technology Company

CURIOUS MINDS

3

As a vibrant science and technology company, we believe in science as a force for good.

We make a positive difference in millions of people’s lives every day.

DEDICATED

WE ARE

TO HUMAN PROGRESS Our passion for science and technology is what drives our 57,000 employees in 66 countries to find solutions to some of today’s toughest challenges and create more sustainable ways to live.

We are here for people at every step, helping to create, improve and prolong life. We deliver personalized treatments for serious diseases and enable people to achieve their dream of becoming parents. We empower the scientific community.

Our tools, services and digital platforms make research simpler, more exact, and help to deliver breakthroughs more quickly.

Our solutions accelerate access to health by ensuring tests are accurate and the medicine we take can be trusted. We brighten the world around us. Our science sits inside technologies that are changing the way we access and display information. We are making the future of mobility safer, homes and devices smarter and technology more sustainable.

Thanks to the constant curiosity of our employees, we are making discoveries that can change the landscape of entire industries. For more than 350 years, we’ve been pushing the boundaries of what’s possible, and we’ll continue to do so in the years to come.

3

803

138 NATIONS

57000 APPROXIMATELY

PERFORMANCE MATERIALS

2129

5599

LIFE SCIENCE

EMPLOYEES WORLDWIDE 7800 IN RESEARCH & DEVELOPMENT

1922 HEALTHCARE

LATIN AMERICA (6 %)

2019 EBITDA PRE BUSINESS SECTOR (€ MIO)

NORTH AMERICA (26 %)

KEY FIGURES

HEALTHCARE

6864 LIFE SCIENCE

2574 PERFORMANCE MATERIALS

2019 NET SALES BY BUSINESS SECTOR (€ MIO)

2019

2018

NET SALES

16.2 BN €

14.8 BN €

EBITDA PRE

4.4 BN €

3.8 BN €

MARGIN

27.1 %

25.6 %

R&D COSTS

2.3 BN €

2.2 BN €

BUSINESS FREE CASH FLOW

2.7 BN €

EMPLOYEES

57071

2.5 BN €

2019 SALES BY REGION (€ MIO)

591 MIDDLE EAST & AFRICA (4 %)

4735 EUROPE (29 %)

14.5 2017

14.8

16.2 2019

2018

51749

1012

ASIA/PACIFIC (35 %)

4214 6714

As a vibrant science and technology company, we believe in science as a force for good.

We make a positive difference in millions of people’s lives every day.

NET SALES IN BILLION (€)

We are known as Merck internationally, except in the United States and Canada where we operate as EMD Serono in the biopharmaceutical business, Millipore Sigma in the life science business, and EMD Performance Materials in the hightech materials business.

DEDICATED

TO HUMAN PROGRESS Our passion for science and technology is what drives our 57,000 employees in 66 countries to find solutions to some of today’s toughest challenges and create more sustainable ways to live.

We are here for people at every step, helping to create, improve and prolong life. We deliver personalized treatments for serious diseases and enable people to achieve their dream of becoming parents. We empower the scientific community.

Our tools, services and digital platforms make research simpler, more exact, and help to deliver breakthroughs more quickly.

Our solutions accelerate access to health by ensuring tests are accurate and the medicine we take can be trusted. We brighten the world around us. Our science sits inside technologies that are changing the way we access and display information. We are making the future of mobility safer, homes and devices smarter and technology more sustainable.

Thanks to the constant curiosity of our employees, we are making discoveries that can change the landscape of entire industries. For more than 350 years, we’ve been pushing the boundaries of what’s possible, and we’ll continue to do so in the years to come.

4

HEALTHCARE

HEALTHCARE

AS

ONE FOR PATIENTS We are dedicated to working As One for Patients, which aims to design the future of healthcare with treatment options to challenge difficult diseases and help create, improve and prolong life.

5

6

HEALTHCARE

Global mega trends, like the growing prevalence of chronic diseases and higher life expectancy, continue to drive demand for new treatments. To meet this demand, we aim to develop high-quality, first-tomarket, best-in-class therapies.

More than 72 million patients use our General Medicine and Endocrinology (GM&E) medications every day. Our medicines have earned the trust of patients, physicians and others by changing the course of diseases like diabetes, hypertension, growth hormone disorders and hypothyroidism.

We are the only company to support aspiring parents at every step of the fertility journey through our 360° portfolio of state-of-the-art therapeutics, technologies and services.

We help experts and clinics personalize treatments, standardize processes and connect all of the dots across the fertility cycle to maximize success rates.

More than 3.6 million babies have been born with the help of our products.

We provide the innovations that matter most to people living with cancer.

With an emphasis on biology-driven research, delivering personalized treatment options that address unmet needs in cancer is a top priority for Merck.

Our oncology franchise focuses on three specific scientific platforms to develop the next generation of our portfolio: Immuno-oncology, DNA damage response and oncogenic pathways. We prioritize assets to ensure they uniquely meet patient needs by exploring an array of targets and focusing on the modalities most apt to reduce disease burden.

Backed by more than 20 years of experience in multiple sclerosis (MS), we remain committed to finding solutions for patients’ unmet needs.

Our MS product portfolio contains the only shortcourse oral treatment for MS and a well-established disease-modifying injectable drug. We also have a robust immunology pipeline which focuses on new therapies with the potential to modulate key mechanisms in other chronic diseases, like systemic lupus erythematosus, rheumatoid arthritis and osteoarthritis.

Our R&D pipeline positions us to become a global specialty innovator in oncology, immuno-oncology, neurology, and immunology — which covers MS as well. With patients at the center of all our efforts, our goal is to transform innovative research into medicines that bring value to patients in need. Our research and development is bolstered by collaborations and external innovation to strengthen our technology base, enhance our scientific capabilities and advance our pipeline. We have entered into a number of strategic collaborations with other well-known companies to evaluate combinations with a range of innovative medicines.

7

HEALTHCARE

OUR PORTFOLIO ADDRESSES THERAPEUTIC AREAS SUCH AS: FERTILITY

Infertility is a treatable medical condition. Men and women are equally affected, but they may need different resources to support them on their fertility journey.

As an innovation-driven market leader with long-standing expertise in fertility, we are committed to providing fully connected solutions that empower fertility experts and clinics to continuously improve reproductive outcomes.

GENERAL MEDICINE & ENDOCRINOLOGY

We are committed to improving outcomes in cardiometabolic and endocrine conditions, such as diabetes, hypertension, growth hormone disorders and hypothyroidism.

of patients — as well as foster debate amongst the MS community in an effort to improve patient care outcomes.

ONCOLOGY AND IMMUNO-ONCOLOGY

The number of people receiving new cancer diagnoses continues to increase annually and is predicted to rise to 29.5 million by 2040 [1].

This knowledge powers our relentless drive and approach in discovering, developing and delivering a diverse range of breakthrough therapies in the hope we can help turn cancer patients into cancer survivors.

With our five innovation hubs around

NEUROLOGY

The treatment journey for multiple sclerosis can be challenging and we aim to make that experience as stress-free as possible; that is why we developed options aimed at lessening the burden of treatment, improving adherence and making drug administration more convenient. In order to do the above successfully, we are continuing to expand our understanding of the overall challenges and needs

OUR INNOVATION HUBS the world, we foster innovation beyond our pipeline aspirations, such as artificial intelligence (AI)enabled health solutions.

Our focus within this field is to explore new AI-based technologies, products and services that could impact the medical and healthcare industries across the value chain

[1] The Global Cancer

Observatory (GCO):

CANCER TOMORROW.

by increasing efficiency, saving costs and improving customer experiences.

More information

8

HEALTHCARE

HEALTHCARE

Personalized medicine in cancer treatment is an approach that allows doctors to select the right treatments for a patient based on detailed molecular information of their tumor — which is usually obtained by testing a tissue biopsy. Liquid biopsies are set to transform the landscape of cancer diagnostics.

HOW WILL LIQUID BIOPSY TRANSFORM CANCER DIAGNOSTICS ?

THE

LIQUID BIOPSY TRANSFORMING CANCER DIAGNOSTICS AND TREATMENTS

Liquid biopsies also offer a much less invasive alternative to the standard tissue biopsy, which translates into less pain, a lower risk of complications and is more convenient for the patient. This type of test also enables doctors to get faster results, more regularly, to better monitor the tumor response and adapt a person’s treatment if necessary. Getting laboratory results from a liquid biopsy typically takes less than ten working days — and in the future, there is even the potential for on-the-spot analysis [1].

9

Many biopsies are relatively easy to collect when it comes to tissues from the mouth, skin, or breast; but this often isn’t true for tumors that lie deep inside As a cancer grows and spreads, it evolves. As a rethe body, such as in the lung, liver or sult of this evolution, the molecular pancreas. In cases where the biopsy make-up of different tumors can vary A liquid biopsy isn’t easy to collect, taking a biopsy will greatly — even different areas of the is a diagnostic tool same tumor can have distinct gene usually involve the patient undergoing an invasive procedure that may even alterations. that plays a require a general anesthetic. Additionkey role in precision Because of tumor variability, a bioally, getting the results from a tissue medicine. biopsy may take as long as one or two marker test based on a single tissue [1] months . biopsy might provide an incomplete picture of a patient’s cancer. Liquid biopsies, on the other hand, even open up the possibility of capturing Therefore, this liquid biopsy alternative to conveninformation about every tumor in a person’s body. tional tissue biopsy that allows for less invasive, less painful and faster testing may have the potential to There has been significant progress in the diagnostic transform the way cancer is diagnosed and treated. field. Some liquid biopsy tests have even already reached the clinic for use, which marks a major step WHAT IS LIQUID BIOPSY? forward in cancer diagnostics. Our scientists are Liquid biopsy is a diagnostic approach that uses actively pursuing cutting-edge research programs a blood sample to identify tumor biomarkers. The to develop and validate liquid biopsy tests that can blood or plasma diagnostic approach is advantageous identify which cancer patients may benefit from and offers the best representation of what’s going on targeted drugs. inside the person’s body — especially if it’s not known where the tumor is or if there are metastases in different organs.

[1] A Worthy Ally for Tracking Tumors in Realtime, by Dennis Merkle

10

LIFE SCIENCE

LIFE SCIENCE

EMPOWERING THE

SCIENTIFIC COMMUNITY

We provide infinite solutions to solve the toughest problems in life science in collaboration with the global scientific community. Our tools, services and digital platforms empower scientists and engineers at every stage, helping deliver breakthrough therapies faster.

11

12

LIFE SCIENCE

Our Life Science experts are committed to galvanizing others with limitless possibilities of what science can achieve. We offer cutting-edge technologies, highquality products and innovative services for R&D and the manufacturing of biologics and novel therapies.

Our dedication towards customer experience extends from the lab to our e-commerce platform, which connects scientists in nearly every country with the products, publications and technical expertise needed to advance research, manufacturing and development at a faster pace. Our work is helping to redefine the industry as we know it, partly because we believe science should know no bounds.

Since the human genome was fully decoded 16 years ago, gene editing and novel modalities have rapidly evolved.

Cell and gene therapies provide life-saving treatments to many patients. Our biopharmaceutical and biomanufacturing services address all phases of such therapeutic developments, which in turn help to deliver cutting-edge, regenerative medicines to our customers.

With CRISPR technology, the DNA of an organism can be edited; furthermore, gene sequences within a cell can be separated or even replaced. These possibilities are coupled with enormous responsibility; therefore, we support research that deals with genome editing when it complies with statutory regulations, has carefully considered all ethical standards, and has a clearly defined bioethics policy.

Factors such as an aging global population and an increase in chronic diseases are catalysts for a new era of advanced discovery in drug manufacturing.

Developments in biologics and therapies have a great potential in treating illnesses where no other options are available. Despite this promising potential, the clinical development journey of a new biologic is a long and challenging process that we are working on to strengthen and evolve. To aid clinical development, our BioContinuum™ Platform is ushering in the next generation of bioprocessing that is connected and fully continuous. As a result, our strategic building blocks, which include our BioContinuum™ Platform, have the potential to accelerate access to recently developed, life-saving therapies that address the healthcare needs of underserved populations.

With today’s labs of the future, laboratory informatics has leveraged technology and accelerated discovery by optimizing operations for our scientists and customers.

Optimized workflows empowered by connectivity and efficiency are enhancing digital lab productivity.

R&D expertise, combined with a comprehensive portfolio, allows us to deliver innovative technologies that make research and biotech production simpler, faster and safer.

From our BrightLab™ connected electronic lab notebook to our LANEXO™ lab management system to the unified and efficient access to lab data made possible

by BSSN Software, which we acquired in 2019, we offer customers a variety of comprehensive, digital products and IoT solutions for safety, compliance, and inventory and instrument management.

13

LIFE SCIENCE

WE PROVIDE STATE-OF-THE-ART TOOLS, TECHNOLOGIES AND SERVICES IN FIELDS SUCH AS: CLINICAL AND DIAGNOSTICS

From concept to clinic, we provide in-vitro diagnostic manufacturers with the broadest offering of raw materials, equipment and services needed for their assay development, scale-up and manufacturing needs.

EMERGING BIOTECH

to accelerate and translate basic discoveries into practical applications for human health and beyond.

INDUSTRIAL

Manufacturing and distributing quality products and services in an ever-changing and competitive world is a challenge that we help our customers tackle.

Having the right partner for emerging biotech is essential for the long, costly and complex journey from discovery to commercialization. We help our customers overcome some of those challenges along the way.

PHARMA AND BIOPHARMA MANUFACTURING

ENVIRONMENTAL TESTING

PHARMACEUTICAL RESEARCH

FOOD AND BEVERAGE

PHARMA QUALITY CONTROL

We provide testing solutions that accurately analyze air, water and soil in order to meet international regulatory standards.

As the global population continues to grow and the regulations for food safety change, our customers look to us for reliable testing.

GOVERNMENT AND ACADEMIC RESEARCH

In labs and institutions both large and small, we empower researchers

By working with pharmaceutical and biopharmaceutical manufacturers, we help make life-enhancing drugs a reality.

Delivering potential new medicines is more challenging and complex than ever, but we are dedicated to accelerating drug discovery.

We collaborate, assist and partner with pharmaceutical professionals to enable workflow solutions and to make scientifically-informed decisions possible at every stage of drug development.

More information

19 14

LIFELIFE SCIENCE SCIENCE _ STORY

NEXT-GENERATION

BIOPROCESSING AN EVOLUTION PROPELLING MANUFACTURING TOWARDS CONTINUOUS BIOPROCESSING

LIFE SCIENCE

15

our vision goes beyond continuous manufacturing Navigating the complexities of the biopharmaceutical with our Bio-Continuum™ Platform. Rather than industry requires a wide range of collaborative, simply connecting different operations, we are comprehensive support services that meet unique bringing together the orchestration and management manufacturing and regulatory requirements. Bioof the entire bioprocessing journey — which includes processing systems need to generate accurate and materials, production, testing and analytics — for a reproducible performance day after day. As a result, more efficient production process. To Bio-Processing 4.0 is poised to transform the production process and how Delivering solutions help deliver this orchestration, our BioContinuum™ Platform uses a buildfacilities operate — meanwhile, the imfor today’s ing block approach to provide seamplications for drug manufacturing are less, physical and digital integration. also significant. biomanufacturing

processes while

The BioContinuum™ Platform aims As industry leaders looking to help madeveloping to revolutionize drug manufacturing, nufacturers start benefiting from the setting the standard by improving the change, we are driving the transforleading-edge efficiency of the process, simplifying mation to BioProcessing 4.0 with a technologies its operations, and attaining a level of toolbox approach for a fully optimized for the factories consistency throughout the manufacfuture. By leveraging innovation across turing life cycle. This platform successthe entire ecosystem that extends to of the future. fully delivers solutions for equipment, consumables, services and today’s biomanufacturing processes and also supports digital offerings, we are building a collection of interthe development of cutting-edge technologies for connected solutions rather than relying on one specific manufacturing facilities of the future. technology or process built in a silo.

Continuous processing plays a critical role in bringing the therapies of our customers to market, which are then delivered to patients in a faster and more costeffective way than ever before. Bioprocessing operations are becoming even more streamlined, which reduces the footprint of manufacturing facilities and optimizes development processes. For example, single-use technologies allow scientists to reduce downtime and ramp up production capabilities.

Important therapies used to fight cancer, such as monoclonal antibodies, are adopting continuous bioprocessing for their manufacturing to speed up production and delivery of key treatments. To deliver this next generation of optimized change,

Life Science is committed to driving infinite solutions so that we can optimize processes and evolve, together.

16

PERFORMANCE MATERIALS

PERFORMANCE MATERIALS

ADVANCING

DIGITAL LIVING We are the company behind the companies advancing digital living everywhere. Our main focus is in the electronics market with our materials and solutions which change the way we access, store, process and display information.

17

18

PERFORMANCE MATERIALS

Artificial intelligence (AI), the Internet of Things (IoT) and autonomous driving are creating pressure for the next generation of innovations when it comes to all aspects of data processing. Data communication is growing exponentially at a rate of more than 30 % annually and this data explosion will transform electronics far beyond what today’s systems can handle.

Data needs to be generated, transferred, processed, stored and made comprehensible to people through smart interfaces. We have depicted these five key functions in a “data circle” (see figure).

Wafer processing is another important key manufacturing step for today’s high-end microchips worth mentioning. Wafer processing is when the transistors and memory cells are generated on a silicon wafer by a complex sequence of different process steps.

With the help of Versum Materials and Intermolecular, we now have solutions that cater to the entire scope of wafer processing. Together with our customers, we are working on the next generation of microchips. For example, the new 3D-NAND technology that Merck is currently working on allows a storage chip architecture that can be built up vertically instead of being limited to a two-dimensional structure. This chip architecture makes sure that faster performance can be ensured while reducing the energy requirement.

Our liquid crystal and OLED display solutions enable the interface between man and machine.

Researchers estimate that 80% to 85% of our perception, learning and cognition activities are mediated through vision[1]. Therefore, displays are the key interface between man and machine where visual data is generated and processed.

Strengthened by the recent acquisitions of Versum Materials and Intermolecular, our high-tech solutions will enable the next generation of semiconductors.

Semiconductors are the most critical components of data-driven electronics; they determine the performance in data generation (IoT), transfer (5G), processing (AI) and storage.

We are always thinking beyond current available technologies by researching and developing the next generation of materials for displays. OLED materials, for instance, are ideal for flexible displays that are expected to come in the near future; they transform surfaces into incredibly thin and lightweight displays with brilliant coloration and sharp imagery from every viewing angle. What’s more, OLED materials are extremely energy efficient.

[1] Source: https://medicalfuturist.com/future-of-vision-and-eye-care/

PERFORMANCE MATERIALS

OUR PRODUCTS ENABLE DIGITAL LIVING AND SERVE NUMEROUS INDUSTRIES: ELECTRONICS

We help the semiconductor industry make electronic devices even more powerful by providing highly innovative material-based solutions. In addition, we provide the industry with dissemination equipment to safely and reliably distribute gases and chemicals to semiconductors and display fabs.

Intermolecular’s experimentation platforms and simulation tools even allow our customers to test and develop material combinations customized to their specific applications.

AUTOMOTIVE

We develop high-tech solutions for electronics that help the automotive industry shape the future of mobility. Our products and technologies also give vehicles a unique color, sparkle and protective coating.

COSMETICS

From skin care solutions to color effects, our portfolio of functional and decorative ingredients for the cosmetics industry provides everything needed to create innovative products and define new trends.

We provide advanced materials for displays and beyond. We recently launched foldable and rollable displays. Beyond these foldable and rollable displays, we are applying our liquid crystal (LC) technology to LC windows, which turn buildings into energy savers and facades into eyecatchers. Other innovations include smart antennas, which enable high-speed internet access in rural areas. What was once considered as science fiction technology is possible today thanks to our display materials!

More information

19

20

PERFORMANCE MATERIALS

CREATING THE

MICROCHIPS OF THE FUTURE

LOW DIELECTRIC CONSTANT (Low-k Interlayer Dielectrics (ILD)

PERFORMANCE MATERIALS

Computers used to be as big as a room. Nowadays, computers can fit in your pocket, on your wrist or even be implanted inside your body. This staggering progress has been made possible by the miniaturization of microchip components, such as transistors, which are semiconductor devices that act as tiny switches in circuits and are the heart of our computers.

and hardness required to reduce mechanical defects in very thin ILD layers. Another thing to consider for thin ILD layers is Plasma Induced Damage (PID) of ILD film through side wall exposure which affects the etching and ashing steps during integration, and which can impact the electrical performance of the films.

Balancing the needs of mechanical properties can be critical in developing a successful ILD process The bad news is we’re about to hit a roadblock because for next-generation devices. Merck is therefore the rate of miniaturization of transistors is slowing developing solutions that can bridge down. Manufacturers are running out the gap between strong mechanical of traditional options to create ever Low-k materials properties and reduced PID. smaller circuitry. To enable technoloenable higher gies of the future, the industry needs In addition to working with original new techniques to drive power and performance from performance at a reasonable cost. ultrathin transistors equipment manufacturers (OEMs), Merck also works with individual for smaller, integrated device manufacturers Low-k Interlayer Dielectrics (ILD) and to develop tailored solutions to meet material implementation have been faster and more used to drive the continued scaling of powerful microchips. their ILD needs for next-generation devices. Our work with a variety microelectronic devices for well over a of manufacturers demonstrates decade. As film pitches have shrunk how we are the company behind the companies with technology node advancements, these films have advancing digital living! evolved from dense, single precursor-based carbondoped oxides to porous low-k films. The addition of porosity was necessary to enable faster switching speeds, reduce parasitic capacitance and increase the performance of memory and logic devices.

Merck is the creator, inventor and innovator of highquality low-k materials. We were the first to introduce low-k dielectric platforms to the market and, with our knowledge and capabilities, we continue to innovate this sector. Our dense low-k precursor development and PDEMS® technology enable the semiconductor industry to scale up relative to advanced nodes.

Today, depending on the device manufacturer’s integration scheme, mechanical properties can become very critical due to the higher elastic modulus

21

22

CORPORATE RESPONSIBILITY AND SUSTAINABILITY

CORPORATE RESPONSIBILITY AND SUSTAINABILITY

SCIENCE

AS A FORCE FOR GOOD

We take responsibility for our products, the environment and our neighbors, and aspire to develop products and services that can help solve the major challenges of our time. Our ambition is to generate an added value for both our company and society as a whole.

23

24

CORPORATE RESPONSIBILITY AND SUSTAINABILITY

Our Corporate Responsibility (CR) strategy is built around being a responsible corporate citizen with an underpinning of operating and maintaining our competitive edge. We always pursue a shared value approach and work to make sure the value we create for the company and for society is measurable in terms of its sustainability. We believe that research and technology hold the key to solving global challenges and see our role in helping shape society.

While aligning our activities within areas where we can have the greatest impact, we managed to define three strategic spheres for which our CR strategy and activities revolve around: Global Health, Sustainable Solutions and Broad Minds.

GLOBAL HEALTH:

Our initiatives, programs and partnerships particularly address unmet medical needs in low- and middleincome countries; our non-profit Merck Foundation also focuses on achieving this goal. Hand in hand with our partners, we help provide local solutions and develop treatments. Two examples include how we eliminate the tropical worm disease schistosomiasis and how we fight malaria.

SUSTAINABLE SOLUTIONS:

We are constantly working to improve the sustainability footprint of our products to help our customers achieve their own sustainability goals. To reach these goals, we established systematic and measurable approaches for developing our products, such as our Design for Sustainability program in the Life Science business sector.

BROAD MINDS:

We believe that one’s own cultural environment is inspirational and opens minds to new possibilities — and

it fuels creativity too! As a vibrant science and technology company, we want to take action in a variety of scientific fields. Thus, we support educational programs at schools as well as pioneering research in academia.

IT IS IN OUR DNA…

… to search for answers to some of the most pressing questions of the future. The growing global population, along with an increase in life expectancy, are dramatically changing our society and the way we live. With our solutions, we are helping to meet the demand for sustainable, personalized and connected products.

Thanks to the constant curiosity of our more than 7,800 R&D professionals, we are discovering and developing technologies that can change the landscape of entire industries. We make an effort to partner with those who share our passion. Our clear goal is to achieve progress for patients, customers and society as a whole.

1 BN +

tablets to treat the tropical worm disease schistosomiasis have been provided free of charge since 2007

830 +

Life Science products are manufactured following the Principles of Green Chemistry

€ 46 MIO spent on community-related activities in 2019

CORPORATE RESPONSIBILITY AND SUSTAINABILITY

25

GOING

GREEN ECO-FRIENDLY ALTERNATIVES TO CONVENTIONAL CHEMICALS With our Green Chemistry program, we are helping our customers contribute to the UN’s Sustainable Development Goals.

Solvents are used for a variety of purposes, such as dry cleaning, printer ink cartridges and nail polish remover. What’s the problem with solvents? Most of them are not particularly eco-friendly and are subject to increasingly stringent regulatory restrictions. To address these issues, we have joined forces with australian Circa Group and the University of York (UK) to launch a “greener” solvent called Cyrene™.

Bio-derived from readily available renewable raw materials, Cyrene™ is manufactured from waste cellulose materials extracted from the Monterey pine (pinus radiata), a softwood lumber that is very popular for reforesting fallow land. Cyrene™ is manufactured in just two steps. The manufacturing process is almost energy-neutral and conserves water. This greener solvent is a safer alternative to conventional substances that are under increasing regulatory restrictions due to their associated toxic properties; and with this alternative, we are addressing SDG 12 (Responsible Consumption and Production).

More information

31

3 QUESTIONS

32

CLOSING WORDS _ CEO

WHAT DOES STAND FOR AS A COMPANY? At Merck, the force that drives us is our purpose: We are curious minds dedicated to human progress. Science is at the heart of everything we do. We work to achieve technological progress that benefits us all – and we have been doing so for more than 350 years.

CAN SCIENCE & TECHNOLOGY BE VIBRANT? Science enables us to develop new technologies that are needed.

Some examples include treating serious diseases, helping researchers worldwide develop new therapies and shaping the digital revolution. We aim to improve the lives of millions of people through our research and our products. This aim, to us, makes science and technology vibrant!

DOES SUSTAINABILITY MATTER AT ?

While economic success is important, scientific curiosity and responsible entrepreneurship have made Merck strong for centuries; and they are the foundation for a sustainable future.

We want to create a shared value for our customers, patients, our owners and society as a whole – both for our businesses and for beyond.

“Technology is a key to human progress.”

Stefan Oschmann CHAIRMAN OF THE EXECUTIVE BOARD AND CEO OF MERCK

W.84010.3

Published in July 2020

by Merck KGaA Group Communications Frankfurter StraĂ&#x;e 250 64293 Darmstadt, Germany +49 6151 72-0 service@merckgroup.com MERCKgroup.com

More information